Background: Neutrophil gelatinase-associated lipocalin (NGAL) appears to be a promising biomarker for the early diagnosis of acute kidney injury (AKI); however, a wide range in its predictive value has been reported.
A cute kidney injury (AKI) is a frequent and serious complication of hospitalized patients associated with substantial morbidity and mortality. [1] [2] [3] Despite significant advances in our understanding of the pathophysiologic characteristics of AKI, several interventions for AKI have been proved ineffective. [4] [5] [6] This failure is caused in part by the lack of real-time sensitive and specific renal biomarkers to allow the early diag-nosis of impending AKI. In current clinical practice, serum creatinine level and urine output are the most frequently used indicators of renal dysfunction despite their known limitations. They have limited sensitivity and specificity and creatinine level has a slow rate of change, thus limiting their usefulness in the early detection of AKI. 7 Consensus groups, such as the Acute Dialysis Quality Initiative (ADQI), the AKI Network (AKIN), and the American Society of Nephrology, have set the development and validation of novel biomarkers of AKI as a priority. 8, 9 Early detection of AKI could permit the institution of timely renal salvage therapies, which, with associated monitoring of response to therapy, may result in preserved renal function and avoidance of renal replacement therapy (RRT) requirement and perhaps translate into improved patient morbidity and mortality.
Genomic, transcriptomic, and proteomic techniques have identified neutrophil gelatinaseassociated lipocalin (NGAL) as an early marker of AKI. 10, 11 In experimental and clinical studies, NGAL has been investigated extensively and would appear to be one of the most frequently investigated and most promising early biomarkers of AKI. NGAL has been investigated across a range of different clinical settings of AKI, such as after cardiac surgery, [15] [16] [17] in critically ill patients, 18, 19 in patients receiving intravenous contrast media infusion for coronary angiography, 20, 21 and in patients admitted to the emergency department. 14 It also has been studied in both adult 15, 17 and pediatric 13, 16, 18, 19 populations and has been measured in urine and plasma/ serum using "research-based" assays (NGAL Rapid enzyme-linked immunosorbent assay [ELISA] kit; Bioporto, Gentofte, Denmark) 13, 15 versus measurement using standardized clinical laboratory platforms (Triage kit [Biosite Inc, San Diego, CA] or ARCHITECT platform [Abbott Diagnostics, Abbott Park, IL]). 16, 17 However, with accumulating evidence, conflicting observations raise concern about the robustness of NGAL as a biomarker. To address this issue, we performed a systematic review and meta-analysis of observational studies to estimate the diagnostic and prognostic accuracy of NGAL and identify potential confounders or effective modifiers of its value in AKI. We hypothesized that NGAL level is of diagnostic and prognostic value, both overall and across a range of subgroups developing AKI; urine and plasma/ serum NGAL levels are both valuable for the early diagnosis of AKI; NGAL level performs better in children; and there might be an advantage for standardized measurement of NGAL with clinical laboratory platforms.
METHODS

Data Sources and Search Strategy
The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines for the conduct of meta-analyses of observational cohort studies 33 were followed. Two investigators (M.H. and P.D.) independently searched MEDLINE (through PubMed interface), EMBASE, CENTRAL, and Congress abstracts (to May 31, 2009 ) to identify potentially relevant articles or abstracts. Our search included 1 search term: neutrophil gelatinase-associated lipocalin or NGAL. There were no language restrictions. We reviewed the bibliographies of all selected articles to identify additional relevant studies.
Study Selection
Two reviewers (M.H. and P.D.) independently screened studies identified for inclusion and determined study eligibility. Disagreements were resolved by a third opinion (R.B.). Selection was restricted to published prospective cohort studies of humans investigating the diagnostic or prognostic accuracy of NGAL level to predict AKI, initiation of RRT, and in-hospital mortality. Trials enrolling patients in interventional studies and those exclusively with AKI were excluded.
Data Extraction and End Points
Most observational studies published for NGAL used different AKI definitions and timing of NGAL measurement, rendering data synthesis difficult, if not impossible. A custommade standardized data collection sheet (Item S1; provided as supplementary online material available with this article at www.ajkd.org) was developed a priori (R.B., M.H., P.D., A.H.-F., and S.M.B.) for uniform definition of the primary study end point (prediction of AKI) and timing of NGAL measurement in relation to the diagnosis of AKI. This data sheet was sent by e-mail to each author of the studies selected and included the request for documentation and recalculation of the following variables: setting of AKI (patients after cardiac surgery, patients after application of contrast agents for coronary angiography, patients admitted to the intensive care unit, and patients admitted to the emergency department), sample size, age, sex, baseline serum creatinine level, number of patients with chronic kidney disease (estimated glomerular filtration rate Ͻ 60 mL/min using the 4-variable Modification of Diet in Renal Disease [MDRD] Study equation 34 ), number of patients developing AKI (primary end point), those receiving RRT, and those who died in-hospital (secondary end points). AKI
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was defined according to the creatinine criteria of the RIFLE classification 35 (increase in serum creatinine Ͼ 50% from baseline within 7 days) or as contrast-induced nephropathy (increase in serum creatinine Ͼ 25% or 0.5 mg/dL in adults 36 or Ͼ 50% in children within 48 hours). 23 Such a time limit for the RIFLE classification was not officially set, but was implied by the general view of the ADQI Consensus Conference Group that AKI should occur acutely over a few days to a week. In addition, the data sheet requested information about the biological material NGAL was measured in (urine and plasma/serum) and the measurement method (research-based assays vs standardized clinical laboratory platforms) and antibodies used. The authors of each study determined the paired sensitivity and specificity (95% confidence interval [CI] ) for the cutoff value of NGAL calculated to be closest to the left upper corner of the receiver operating characteristic (ROC) space to predict AKI, RRT initiation, or in-hospital mortality. The timing of NGAL measurement in relation to the development of AKI was considered. When the time of renal insult was known, NGAL measurement within 6 hours was used, and when the time of renal insult was unknown, measurement 24-48 hours before the diagnosis of AKI was used for calculation of performance characteristics. In addition, calculation of the area under the curve for the ROC (AUC-ROC) with 95% CIs was requested for the primary and secondary end points. Data about the quality of NGAL sample collection, processing, and storage also were recorded.
Of 26 requests for completion of the data collection sheet sent to authors, 19 completed forms with 23 data sets (4 studies measured NGAL in both plasma/serum and urine; 
Statistical Analysis
The publication bias of included studies was assessed using effective sample-size funnel plot (diagnostic odds ratio [DOR] values vs sample size of each study). 37 The primary statistical analysis was based on a hierarchical bivariate generalized linear mixed model as proposed by Harbord et al 38 using the Stata program METANDI (StataCorp LP, College Station, TX) by Harbord. Based on this model, the elliptical joint confidence region for sensitivity and specificity and a summary ROC curve were constructed and the DOR and 95% CI were determined. In addition, AUC-ROC values with 95% CI and cutoff values for NGAL weighted for sample size were pooled. [39] [40] [41] An AUC-ROC Ͼ 0.70 defines a useful risk predictor. 42 The I 2 statistic was calculated to determine the proportion of between-study variation in the AUC-ROC caused by heterogeneity, with suggested thresholds for low (25%-49%), moderate (50%-74%), and high (Ͼ75%) values.
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RESULTS
Search Results and Study Characteristics
The electronic database searches identified 244 citations of studies and abstracts. After evaluating these citations and the bibliographies of included studies, we included 19 studies with 23 data sets. [13] [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] These comprised data from 4 Note: Conversion factor for serum creatinine in mg/dL to mol/L, ϫ88.4. Abbreviations and definitions: CIN, contrast-induced nephropathy; CS, cardiac surgery-associated acute kidney injury; ED, emergency department; ICU, intensive care unit; NGAL, neutrophil gelatinase-associated lipocalin.
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conference abstracts. 27, 29, 30, 32 A flow chart detailing the process of study identification and selection is shown in Fig 1, and characteristics of included studies are listed in Table 1 . The Cohen statistic for agreement on study inclusion was 0.94. Three authors of 3 additional studies published to date in only abstract form (without AUC-ROC values, sensitivity, or specificity) decided not to provide the data requested because of possible impediment of their original publication in preparation. One research group responsible for 4 publications unfortunately was not able to calculate the AUC-ROC because of the lack of an appropriate statistical software program.
Although all studies were published in English, they represent an international experience, having been conducted in 8 countries. All studies were single-center trials and excluded patients on long-term hemodialysis therapy before enrollment in the study. A total of 2,538 patients (mean sample size, 123 [95% CI, 67-179]; median, 72 [25th-75th percentiles, 50-123]) was enrolled in these studies. Study populations included adults and children studied in different AKI settings. Studies most frequently investigated AKI after cardiac surgery, followed by AKI in critically ill patients and after exposure to contrast media for coronary angiography. More studies measured NGAL in urine compared with plasma/serum and in adults compared with children. NGAL measurements most commonly were obtained using research-based assays. [13] [14] [15] [18] [19] [20] [22] [23] [24] [26] [27] [28] 30, 31 However, some recent studies have used standardized clinical laboratory platforms with a chemiluminescent microparticle assay, such as the Triage kit, for plasma NGAL 17, 25, 29, 32 and the ARCHITECT platform for urine NGAL. 16 
Quality Assessment
All studies originally were designed to examine the diagnostic accuracy of NGAL level, enrolled consecutive patients prospectively, and had clearly defined eligibility criteria and reasons for patient exclusion ( Table 2 ). For primary and secondary analyses of the diagnostic accuracy of NGAL, 2 studies 15,17 provided samplesize estimation and the remaining studies used a convenience sample size. However, for the prognostic accuracy of NGAL level, all studies used a convenience sample size. In all studies, the spectrum of patients was representative of patients who might receive the test in practice. Serum creatinine was used and measured using a modified Jaffé method. No patient underwent renal scintigraphy for verification of AKI diagnosis. Several studies reported investigators' involvement with industry sponsors. In no case was data extraction, statistical analysis, or drafting of the manuscript influenced by the sponsors. Laboratory personnel measuring serum creatinine in the hospital pathology department and clinicians were not aware of the NGAL source and results, which was measured by spatially divided "research" personnel. Research personnel were blinded to sample sources, clinical outcomes, and serum creatinine concentrations. All studies had similar sample collection and processing. Most stored samples at Ϫ80°C; however, 2 studies stored samples at Ϫ20°C, 1 of those for short term 31 and 1 for long term. 26 There was no evidence of significant publication bias for the primary or secondary outcomes (regression test of asymmetry, P Ͼ 0.2). Three studies directly compared the performance of NGAL level with that of serum creatinine level. 14, 17, 31 For NGAL and serum creatinine levels, Nickolas et al 14 reported similar AUC-ROC (0.95 vs 0.92) values for the early diagnosis of AKI defined as a new-onset 1.5-fold increase in serum creatinine level or a 25% decrease in estimated glomerular filtration rate from baseline in a cohort of patients admitted to the emergency department. Makris et al 31 and Haase-Fielitz et al 17 found a significantly greater AUC-ROC value for NGAL level at admission to the intensive care 
Evidence Synthesis
In Table 3 , true-positive, false-positive, falsenegative, true-negative, paired sensitivity and specificity, and cutoff values of individual studies are listed for NGAL level to predict AKI. In Table 4 , the same indices for NGAL level to predict RRT or in-hospital mortality are listed.
In Table 5 , the diagnostic and prognostic accuracy of NGAL weighted for sample size is shown. Across settings of AKI, [13] [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] we found a DOR of 18.6 for NGAL at sensitivity of 76.4% and specificity of 85.1% (Fig 2) and AUC-ROC of 0.815.
Subset analyses showed some variability in DOR and AUC-ROC values. NGAL level was of diagnostic value for AKI after cardiac surgery, in critically ill patients, after contrast media use, and in patients admitted to the emergency department. The best predictive performance of NGAL level was found in the setting of AKI after exposure to contrast agents 20, 23, 30 (DOR, 92.0; AUC-ROC, 0.894). The specificity of NGAL level for prediction of AKI after exposure to contrast media was Ͼ 95%, whereas it was ϳ75% after cardiac surgery and in critically ill patients at sensitivity of ϳ70%-75% in all AKI settings.
The DOR and AUC-ROC of plasma/serum NGAL level [13] [14] [15] [16] [17] [18] [19] [22] [23] [24] [25] 29, 32 (DOR, 17.9; AUC-ROC, 0.775) were similar to those of urine NGAL level [13] [14] [15] 16, 18, 20, 22, 24, [26] [27] [28] 30, 31 (DOR, 18.6; AUC-ROC, 0.837) in the prediction of AKI, with a slightly higher cutoff value for urine NGAL (Table 5) . However, the value of NGAL level to predict AKI in children 13, 16, 18, 20, 23, 25 Table 5 ). The study by Xin et al 28 was excluded from this comparison because both children and adults were enrolled (Table 5) .
Across all settings of AKI, we investigated the diagnostic accuracy of NGAL level for AKI when measured using standardized clinical platforms 16, 17, 25, 29, 32 versus research-based assays.
13-15,18-20,22-24,26-28,30,31 Performance characteristics of NGAL level from this analysis also are listed in Table 5 . We found higher DOR and AUC-ROC values for standardized assays (DOR, 25.5; AUC-ROC, 0.830) compared with individually developed research-based assays (DOR, 16.7; AUC-ROC, 0.732).
The cutoff NGAL concentration for optimal sensitivity and specificity to predict AKI across all settings ranged from 100-270 ng/mL, with higher values for adults (170 ng/mL) compared with children (100-135 ng/mL; Table 5 ).
However, there was large agreement on a cutoff value Ͼ 150 ng/mL when NGAL was measured using standardized platforms, contrasting with large variability in cutoff values derived from research-based NGAL assays (Table 5) .
Despite some deviation, there was broad agreement between values originally reported and those recalculated for the meta-analysis. Generally, NGAL level performance improved when the definition of AKI used in this meta-analysis was more severe compared with the original publication and vice versa, in accordance with a previous observation. 44 The incidence of RRT reported in the included studies was 4.3%, and in-hospital mortality, 5.4%. In Table 5 , data for the prognostic accuracy of NGAL level are listed. NGAL level appears to be a useful prognostic tool with regard to the prediction of the initiation of RRT (DOR, 12.9; AUC-ROC, 0.782; Fig 3) and, with some limitation, in-hospital mortality (DOR, 8.8; AUC-ROC, 0.706; Fig 4) . 
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DISCUSSION
The need for a simple, accurate, and minimally invasive marker of AKI has been a limiting factor in clinical nephrology research and practice. Although serum creatinine level is the current standard as such a marker, its limitations are well known and include its dependence on age, sex, and muscle mass. 7, 17 More accurate methods, such as radiolabelled tracer clearances, are invasive, may involve radiation, and require several hours to perform. Of several recently characterized novel renal biomarkers, [45] [46] [47] NGAL has received the most interest. This interest has increased with the advent of point-of-care or rapid central laboratory measurement techniques for the standardized measurement of NGAL in clinical settings. However, a wide range of predictive values of NGAL for AKI have been reported across observational cohort studies. 13, 22, 44 We performed a systematic review and metaanalysis to clarify the predictive value of NGAL for the early diagnosis of AKI, both overall and across a range of subgroups developing AKI. We also investigated the predictive value of plasma/ serum NGAL with urine NGAL level, applied in children versus adults, and measured using research-based versus standardized assays for the early diagnosis of AKI. First, we found NGAL level to be a useful early predictor of AKI, both overall and across a range of clinical settings. Second, urine or plasma/ serum NGAL levels performed similarly well. Third, the performance of NGAL level improved when standardized clinical laboratory platforms with a cutoff NGAL concentration Ͼ 150 ng/mL were used, in comparison to research-based assays. Finally, NGAL level had prognostic value for clinical outcomes, such as initiation of RRT and mortality.
In the literature, different definitions of AKI, 1, 35, 48 various settings of AKI, 14, 16, 21, 26 and varying timings of NGAL measurement with regard to a renal insult have been used to assess the predictive value of NGAL level, thus creating effective modifiers of NGAL's usefulness as a biomarker. 44 Also, a clear cutoff NGAL concentration for the detection of AKI has not yet been reported. This is the first meta-analysis of the performance of NGAL as a predictor of AKI and represents an attempt to address these issues and provide guidance for its future use. Our metaanalysis provides a systematic overview summa- Abbreviations: FN, false negative; FP, false positive; NGAL, neutrophil gelatinase-associated lipocalin; p, plasma; TP, true positive; TN, true negative; RRT, renal replacement therapy; u, urine. AKI 7 rizing data from observational studies for the diagnostic and prognostic accuracy of NGAL level to predict AKI using a uniform definition of AKI and standardized timing of NGAL measurements in relation to the renal insult. This approach enables direct comparison of results of these studies. This meta-analysis found that overall, NGAL is a valuable renal biomarker in all settings of AKI investigated. Although useful in adults, NGAL level has lower predictive value with wider CIs for AKI prediction compared with children. These findings deserve further investigation focusing on the influence of comorbidities, source of NGAL, and pathophysiologic characteristics of AKI.
NGAL to Predict
Against the background that a renal biomarker with optimal performance in blood or urine is needed and the uncertainty of whether NGAL level performs better in urine [13] [14] [15] [16] 18, 20, [22] [23] [24] [26] [27] [28] 30, 31 or plasma/serum, 13, 17, 19, [22] [23] [24] [25] 29, 32 this meta-analysis adds important data to the literature. Both plasma/ serum and urine NGAL levels appear to perform similarly well and provide a relevant advantage compared with serum creatinine.
The cutoff value for NGAL was Ͼ 150 ng/mL in studies using standardized clinical platforms, whereas higher variability for cutoff and lower specificity were found in research-based NGAL assays. To what extent this cutoff value prevails currently is unknown and needs further investiga- Note: NGAL measured within 6 hours from the time of renal insult or 24 to 48 hours before the diagnosis of AKI. Abbreviations: AKI, acute kidney injury; AUC-ROC, area under the curve for the receiver-operating characteristic; CI, confidence interval; DOR, diagnostic odds ratio; NGAL, neutrophil gelatinase-associated lipocalin; RRT, renal replacement therapy.
a Weighted for study sample size and calculated for NGAL concentration to be closest to the left upper corner of the ROC space. AUC-ROC and NGAL cut-off values denote median (25th-75th percentiles). I 2 values reflect heterogeneity of AUC-ROC values. The study by Xin et al 28 was excluded from separate children or adult analysis because both children and adults were enrolled in this study. Analysis of plasma/serum NGAL and urine NGAL included 4 studies providing data on NGAL's performance measured in both biological materials, plasma/serum, and urine. For patients admitted to the emergency department (excluding prerenal azotemia, n ϭ 541), 14 the predictive performance of urine NGAL for AKI was AUC-ROC of 0.975 (95% CI, 0.957-0.993); sensitivity, 86%; and specificity, 97% at a concentration Ͼ 80 ng/mL.
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tion in large international prospective trials enrolling patients with normal or chronically impaired renal function in both patients developing AKI and those without AKI. However, it might be necessary for each center using NGAL level for early AKI diagnosis to define a specific normal range and cutoff value for each clinical setting.
The quality of data from completed data sheets was sufficient. Smaller studies often reported AUC-ROC values for AKI, but not for the initiation of RRT or in-hospital mortality, most likely because of the low incidence of these events. The effect of this data selection bias is unknown. However, for the primary outcome, completeness of data was achieved.
It is worth noting that in the studies included, the reference standard test for the diagnosis of AKI in current clinical practice was serum creatinine level despite its known limitations. None of the studies included used inulin or radiolabelled tracer-based clearance for more precise validation of NGAL's performance. Also, using NGAL level as a single novel biomarker to predict AKI might not have covered all aspects of the diagnostic pathways for AKI, including kidney ultrasound and urine microscopy. However, NGAL level clearly predicted creatinine-based diagnosis of AKI and its associated morbidity and mortality. In this regard, we found NGAL level to be a useful marker in the early prediction of the initiation of RRT or in-hospital mortality, indicating that this renal biomarker has both diagnostic and prognostic relevance. NGAL was the only novel renal biomarker investigated, and we did not request data for the predictive performance of NGAL level normalized for urine creatinine concentration. However, this ratio was shown to increase transiently despite no change in the biomarker excretion rate simply because of the acute decrease in urine creatinine excretion after renal injury. 49 The influence of race and center-specific measures directed at the prevention of AKI on results of the meta-analysis is unknown. 
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Two of the 3 studies 17,31 directly comparing the performance of NGAL level with that of serum creatinine level reported NGAL level to be superior to serum creatinine level for AKI prediction when measured at the same time. 17, 31 However, the study conducted by Nickolas et al 14 did not find superiority of NGAL level over serum creatinine level predicting subsequent AKI in patients admitted to an emergency department given that patients already presenting with manifest AKI and those with subclinical AKI were pooled. One large study 26 with long-term storage of samples at Ϫ20°C showed a limited predictive value of NGAL level for AKI. Despite concerns of NGAL stability, 50 at this stage, there was no clear justification to exclude the study from this meta-analysis. Of enrolled patients, ϳ70% were from the United States. [13] [14] [15] [16] 18, 19, 22, 23, 25, 26 Although there were 2 studies from China 20,28 and 1 from South America, 27 the generalizability of NGAL value needs further local investigation and validation. We did not use urine output for the definition of AKI because most studies could not provide these data. However, the creatinine criteria of the RIFLE classification for the definition of AKI are considered to be valuable. 51 A custom-made data collection sheet completed and returned by each author was used for all data analyzed. This implied recalculation of all performance characteristics of NGAL level for each study using a uniform definition of AKI and enabled a standardized data synthesis. Also, analysis of the performance characteristics of NGAL was limited to its measurement well in advance of the diagnosis of AKI, emphasizing its value as an early biomarker compared with serum creatinine level.
NGAL measurement is considerably less labor and time intensive than clearance techniques and will cause less patient inconvenience and morbidity. Given that NGAL level shows performance for AKI similar to that of troponin level for myocardial infarction during its clinical implementation period (AUC-ROC in the 0.7 range), 52 NGAL appears to be a promising candidate as an enrollment criterion for clinical trials investigating early novel interventions or therapeutic drug monitoring/safety across settings of AKI. 53 It is possible that the diagnostic performance of NGAL will improve in the future as more studies are completed using standardized platforms rather than research-based assays (similar to what happened with troponin). More studies using standardized platforms with on-site measurement using fresh blood or urine samples from patients in multiple AKI settings may contribute to more robust laboratory implementation of NGAL.
In conclusion, in our meta-analysis of data from 19 studies including Ͼ 2,500 patients, NGAL level appears to be of diagnostic and prognostic value for AKI. When confirmed in large prospective studies, NGAL level should be considered in randomized controlled trials of preventive and therapeutic interventions in AKI. 
